NCT07835282

Brief Summary

Germany on Target Registry (DaZiR) is a prospective, Germany-wide patient registry designed to assess lipid management and low-density lipoprotein cholesterol ( LDL-C) target attainment in adults following acute myocardial infarction (STEMI or NSTEMI). Eligible patients are informed about the registry by treating physicians or their medical teams and receive an individual access link or QR code. Following electronic informed consent and registration, participants provide clinical and follow-up information through the brite™ platform. Clinical data, including LDL-C values and lipid-lowering treatment, can be entered by the participants or obtained from uploaded medical documents. The platform enables participants to follow the course of their LDL-C values and provides reminders for scheduled follow-up data collection. Medical treatment is determined independently by the treating physicians as part of routine clinical care and is not assigned by the registry. The registry aims to assess LDL-C target attainment over time, changes in lipid-lowering treatment, treatment adherence and cardiovascular outcomes following myocardial infarction.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
293mo left

Started Dec 2026

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 10, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 22, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2026

Expected
9.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2036

15 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2050

Last Updated

September 28, 2026

Status Verified

September 1, 2026

Enrollment Period

9.1 years

First QC Date

September 10, 2026

Last Update Submit

September 23, 2026

Conditions

Myocardial Infarction (MI)Dyslipidemias

Keywords

LDL CholesterolLDL-CST-Elevation Myocardial InfarctionSTEMINon-ST-Elevation Myocardial InfarctionNSTEMILipid-Lowering TherapySecondary PreventionCardiovascular DiseaseDyslipidemiaPatient RegistryDigital Health

Outcome Measures

Primary Outcomes (1)

  • LDL-C target attainment

    The primary endpoint of the study/registry is the achievement and maintenance of the LDL-C target level recommended by the current ESC/EAS guidelines for high-risk cardiovascular patients during the follow-up period. Assessment is based on documented LDL-C measurements taken at specified time points (after 6 weeks, 3, 6, and 12 months, as well as during the subsequent long-term follow-up).

    12 months

Secondary Outcomes (15)

  • Absolute change in LDL cholesterol

    Baseline to 60 month

  • Percentage change in LDL cholesterol

    Baseline to 60 Month

  • Body weight

    Baseline

  • Body height

    Baseline

  • Body mass index

    Baseline

  • +10 more secondary outcomes

Study Arms (1)

Patients following acute myocardial infarction

Adults following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) who voluntarily enroll in the Deutschland auf Ziel registry and are prospectively followed through the brite™ platform.

Other: No study-assigned intervention

Interventions

No study-assigned interventionOTHER

Participants receive medical care according to routine clinical practice. The registry does not prescribe or assign lipid-lowering treatment. Lipid-lowering therapies and subsequent treatment changes are documented as part of the observational data collection.

Patients following acute myocardial infarction

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults aged 18 years or older following an acute ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) treated in Germany. Potential participants are identified and informed about the registry by physicians or medical institutions and voluntarily enroll using an individual access link or QR code.

You may qualify if:

  • Age ≥18 years
  • Diagnosis of acute ST-elevation myocardial infarction (STEMI) or non-ST- elevation myocardial infarction (NSTEMI)
  • Provision of informed consent for participation in the registry

You may not qualify if:

  • No informed consent for participation in the registry

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Myocardial InfarctionDyslipidemiasST Elevation Myocardial InfarctionNon-ST Elevated Myocardial InfarctionCardiovascular Diseases

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosisLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Central Study Contacts

Oliver Weingärtner, Prof. Dr. med.

CONTACT

+493641-932-4521oliver.weingaertner@med.uni-jena.de

Lukas Babylon, Dr. rer. nat.

CONTACT

+496051-49084-20lukas.babylon@lipid-liga.de

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 10, 2026

First Posted

September 22, 2026

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

January 1, 2036

Study Completion (Estimated)

December 31, 2050

Last Updated

September 28, 2026

Record last verified: 2026-09